SLC7A6 has also been shown in murine models to regulate glutamine-dependent mTOR activation and decrease sensitivity in pancreatic cancer [33], leading to the hopes of using it as a therapeutic target for pancreatic cells. The gene discussed is SLC7A6; the disease is pancreatic neoplasm.